As a Free StocksGuide user, you can view scores for all 7,029 stocks worldwide.
7 Analysts have issued a HilleVax forecast:
7 Analysts have issued a HilleVax forecast:
Mar '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -77 -77 |
44%
44%
|
EBIT (Operating Income) EBIT | -80 -80 |
43%
43%
|
Net Profit | -107 -107 |
25%
25%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. Its pipeline includes Norovirus and HIL-214. The company was founded by Maurice Hilleman and Tadataka Yamada on March 25, 2020 and is headquartered in Boston, MA.
Head office | United States |
CEO | Robert Hershberg |
Employees | 90 |
Founded | 2020 |
Website | www.hillevax.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.